2026 ASH®
Annual Meeting & Exposition December 12-15, 2026 ▪ New Orleans, Louisiana

Paper Details

Abstracts, authors, affiliations, and disclosures.

Sunday, December 13, 2026
06:00 p.m. - 08:00 p.m.
MCCNO - Hall F
Access, Representation, Population Health, Technology and Procedures, Imaging, Computational Biology, Emerging Technologies, Treatment Considerations, Combination Therapy, Drug Development, Supportive Care, Therapy Sequence, Biological Therapies, Gene Therapy, Non-Biological Therapies, Women’s Health, Adverse Events, Artificial Intelligence (AI), Biological Processes, Pathogenesis, Microbiome, Multi-Systemic Interactions, Clinical Practice (Health Services and Quality), Clinical Guidelines, Patient Safety, Quality of Care, Diseases, Genetic Disorders, Hemoglobinopathies, Sickle Cell Disease, Sickle Cell Trait, Thalassemia, Infectious Diseases, Viral, Bacterial, Research, Translational Research, Clinical Research, Clinical Trials, Epidemiology, Health Outcomes Research, Health Disparities Research, Patient-Reported Outcomes, Real-World Evidence, Registries, Study Population, Human, Adult, Elderly, Pediatric, Young Adult
PAPER

2922 Liver laboratory abnormalities and their association with all-cause mortality in sickle cell disease: Analysis of the sickle cell disease implementation Consortium registry

Franklin Njoku, MD, Judith Nocek, PhD2, Xu Zhang, PhD3, Marwah Farooqui, DO4, Jin Han5, Santosh L Saraf, MD6, Lewis L. Hsu, MD, PhD7, Victor Gordeuk, MD8
1 University of Illinois Chicago Comprehensive Sickle Cell Center, Chicago, Illinois, United States
2 University of Illinois Chicago Comprehensive Sickle Cell Center, Chicago, Illinois, United States
3 University of Illinois Chicago Comprehensive Sickle Cell Center, Chicago, Illinois, United States
4 University of Illinois Chicago Comprehensive Sickle Cell Center, Chicago, Illinois, United States
5 University of Illinois Chicago Comprehensive Sickle Cell Center, Chicago, Illinois, United States
6 University of Illinois Chicago Comprehensive Sickle Cell Center, Chicago, Illinois, United States
7 University of Illinois Chicago Comprehensive Sickle Cell Center, Chicago, Illinois, United States
8 University of Illinois Chicago Comprehensive Sickle Cell Center, Chicago, Illinois, United States

Background
Interpretation of liver laboratory abnormalities in sickle cell disease (SCD) is challenging because several commonly used biomarkers, including aspartate aminotransferase (AST), total bilirubin, and lactate dehydrogenase (LDH), are influenced by chronic hemolysis as well as hepatic injury. Consequently, distinguishing clinically meaningful liver injury from baseline hemolysis remains difficult. We characterized liver laboratory abnormalities, described biochemical liver injury patterns using the R-ratio, and evaluated the prognostic significance of individual liver-related biomarkers in a large multicenter SCD cohort.

Methods
Baseline laboratory and mortality data were analyzed from 2,435 participants enrolled in the Sickle Cell Disease Implementation Consortium (SCDIC) Registry. Liver-related laboratory measures, collected at steady state, included total and direct bilirubin, AST, alanine aminotransferase (ALT), alkaline phosphatase (ALP), albumin, and LDH. Liver injury patterns were classified descriptively using the R-ratio, calculated as (ALT/upper limit of normal [ULN]) divided by (ALP/ULN),  as hepatocellular (R≥5), cholestatic (R≤2 with ALP elevation), mixed (R>2–<5), or no ALT/ALP elevation. Laboratory variables were categorized using clinically relevant thresholds. Marked AST elevation was defined as ≥3× ULN. Death status was analyzed as a binary outcome. Multivariable logistic regression evaluated independent associations between mortality and age, sex, total bilirubin category, albumin category, LDH elevation grade, ALP elevation grade, and AST ≥3× ULN.

Results
The study cohort (N=2,435) had a median age of 27.0 years (IQR 22.0–34.0 years) and was 56.8% female. Among 2,091 participants with available total bilirubin measurements, 1,588 (75.9%) had hyperbilirubinemia >1.2 mg/dL. Direct bilirubin was elevated in 658 of 1,079 tested participants (61.0%), AST in 716 of 2,085 (34.3%), ALT in 366 of 2,087 (17.5%), ALP in 220 of 2,088 (10.5%), and LDH in 1,171 of 1,512 (77.4%). Hypoalbuminemia <3.5 g/dL was present in 138 of 2,077 participants (6.6%). Using the R-ratio, cholestatic (14.6%) and mixed (8.2%) biochemical patterns were more frequent than hepatocellular (0.5%) patterns, while most participants (76.7%) had no ALT or ALP elevation.

The complete-case mortality analysis included 1,497 participants, including 76 deaths. Observed mortality was 4.7% with AST <3× ULN and 29.2% with AST ≥3× ULN. Mortality was 4.3% with ALP within the ULN and 33.3% with ALP ≥2× ULN. Mortality was 4.1% among participants without ALT or ALP elevation, 8.8% among those with a cholestatic biochemical pattern, and 8.1% among those with a mixed/hepatocellular pattern.

After multivariable adjustment, the odds of dying was increased sixfolds for AST ≥3× ULN (adjusted odds ratio [aOR], 6.17; 95%, CI, 2.14–17.83; P<.001), fivefolds for ALP ≥2× ULN (aOR, 5.32; 95% CI, 1.49–18.97; P=.010), fourfolds for albumin <3.0 g/dL (aOR, 4.09; 95% CI, 1.47–11.34; P=.007) and  64% for each 10-year increase in age(aOR, 1.64; 95% CI, 1.21–2.24; P=.002). Total bilirubin category, LDH elevation grade, and sex were not independently associated with mortality. The model demonstrated moderate discrimination (area under the receiver operating characteristic curve, 0.712).

Conclusions
Liver-related laboratory abnormalities are highly prevalent in SCD, but not all liver-associated biomarkers convey equivalent prognostic information. Despite being influenced by chronic hemolysis, marked AST elevation (≥3× ULN)was independently associated with mortality, whereas LDH and total bilirubin, prominent markers of hemolysis, were not. These findings may suggest that marked AST elevations may primarily reflect clinically significant hepatic injury, particularly when accompanied by marked ALP elevation, another independent predictor of mortality. Although ALT is a more specific marker of hepatocellular injury, isolated hepatocellular injury was rare in this unselected cohort for liver injury, likely limiting its independent prognostic contribution. Together, these findings suggest that the severity of individual biochemical abnormalities is more informative than biochemical injury pattern alone. Recognition of these high-risk laboratory abnormalities may facilitate earlier evaluation for progressive liver disease, prompt referral to hepatology, closer longitudinal surveillance, and prioritization of disease-modifying or curative therapies in patients at greatest risk.

Franklin Njoku, MD: No relevant conflicts of interest to declare.